Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
Telaglenastat plus everolimus in advanced kidney cancer
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer
This phase 1 clinical trial looked at the safety, tolerability, [...]
ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
ENTRATA study of telaglenastat in combination with everolimus in patients with kidney cancer
In this video interview Dr Chung-Han Lee from Memorial Sloan [...]
ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer
Results from the ENTRATA clinical trial to assess telaglenastat in [...]
Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer
Telaglenastat is an oral glutaminase inhibitor and this is the [...]
